SCHEMBL1709166

SCHEMBL1709166

COc1ccc(NC(=O)NC(CC(C)C)C(=O)N[C@@H](Cc2ccccc2)C(=O)NC(CC(C)C)C(=O)C2(C)CO2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 19/20 0.79
PSMB8 P28062 17/20 0.79
PSMB2 P49721 16/20 0.79
PSMB1 P20618 15/20 0.79
PSMB9 P28065 15/20 0.79
PSMB10 P40306 14/20 0.79
PSMB11 A5LHX3 13/20 0.79
PSMA7 O14818 13/20 0.79
PSMA1 P25786 13/20 0.79
PSMA2 P25787 13/20 0.79
PSMA3 P25788 13/20 0.79
PSMA4 P25789 13/20 0.79
PSMA5 P28066 13/20 0.79
PSMB4 P28070 13/20 0.79
PSMB6 P28072 13/20 0.79
PSMB3 P49720 13/20 0.79
PSMA6 P60900 13/20 0.79
PSMA8 Q8TAA3 13/20 0.79
PSMB7 Q99436 13/20 0.79
FPR2 P25090 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18875020 1.00 PSMB5 (0.79) PSMB5PSMB8PSMB2PSMB1PSMB9
SCHEMBL2632709 1.00 PSMB5 (0.79) PSMB5PSMB8PSMB2PSMB1PSMB9
SCHEMBL2632873 0.92 PSMB5 (0.68) PSMB5PSMB8PSMB2PSMB1PSMB9
SCHEMBL1709160 0.92 PSMB5 (0.68) PSMB5PSMB8PSMB2PSMB1PSMB9
SCHEMBL18875019 0.92 PSMB5 (0.68) PSMB5PSMB8PSMB2PSMB1PSMB9
SCHEMBL2735637 0.91 PSMB5 (0.77) PSMB5PSMB8PSMB2PSMB1PSMB9
SCHEMBL1709172 0.91 PSMB5 (0.77) PSMB5PSMB8PSMB2PSMB1PSMB9
SCHEMBL18874968 0.91 PSMB5 (0.77) PSMB5PSMB8PSMB2PSMB1PSMB9
SCHEMBL20756646 0.87 PSMB5 (0.77) PSMB5PSMB8PSMB2PSMB1PSMB9
SCHEMBL16024787 0.87 PSMB5 (0.77) PSMB5PSMB8PSMB2PSMB1PSMB9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088762-A1 COMPOUNDS FOR ENZYME INHIBITION ONYX THERAPEUTICS, INC. (US) 2012-04-12 US disclosed
US-8080545-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2011-12-20 US disclosed
US-20100144648-A1 COMPOUNDS FOR ENZYME INHIBITION ONYX THERAPEUTICS, INC. (US) 2010-06-10 US disclosed
US-7691852-B2 Compounds for enzyme inhibition ONYX THERAPEUTICS, INC. (US) 2010-04-06 US disclosed
US-20070293465-A1 Compounds for enzyme inhibition PROTEOLIX, INC. (US) 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088762-A1 COMPOUNDS FOR ENZYME INHIBITION PSME1, PSMB1, PSME3 PSMB5 4/4885PSMB8 20/4885PSMB2 8/4885
US-20070293465-A1 Compounds for enzyme inhibition PSME1, PSMB1, PSME3 PSMB5 4/4885PSMB8 20/4885PSMB2 8/4885
US-20100144648-A1 COMPOUNDS FOR ENZYME INHIBITION PSME1, PSMB1, PSME3 PSMB5 4/4885PSMB8 20/4885PSMB2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.